Logo

Vir and Alnylam Expand Their Existing Collaboration to Develop RNAi Therapeutics Targeting Host Factors for COVID-19

Share this
Vir and Alnylam Expand Their Existing Collaboration to Develop RNAi Therapeutics Targeting Host Factors for COVID-19

Vir and Alnylam Expand Their Existing Collaboration to Develop RNAi Therapeutics Targeting Host Factors for COVID-19

Shots:

  • The collaboration will evaluate RNAi therapeutics targeting three host factors required for SARS-CoV-2 infection- including ACE2 and TMPRSS2. The third target is expected to emerge from Vir’s ongoing genomics efforts for identifying novel host factors relevant to COVID-19
  • Under the amended collaboration- Vir will be responsible for the development of selected DCs and the commercialization of any therapy- developed under the collaboration. Alnylam will either have an option to share equal profits & losses associated with each COVID-19 program or may receive milestones & royalties emerging from the collaboration
  • The additional targets expanded the companies’2017 collaboration and the amendment to that agreement announced in Mar 2020- to now develop novel siRNAs for up to 9 infectious disease targets

Click here to­ read full press release/ article | Ref: Alnylam | Image: Alnylam


Tuba

Tuba was Senior Editor at PharmaShots. She was curious, creative, and passionate about recent updates and innovations in the life sciences industry. She covered Biopharma, MedTech, and Digital health segments. Tuba also had an experience in digital and social media marketing and ran the campaigns independently. She can be contacted at connect@pharmashots.com.

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions